Incidence of Demodex folliculorum in patients with end stage chronic renal failure

Basit Öğe Kaydı
dc.authoridtaskapan, hulya/0000-0001-8736-4779
dc.authorwosidtaskapan, hulya/ABI-7737-2020
dc.contributor.authorKarincaoglu, Y
dc.contributor.authorSeyhan, ME
dc.contributor.authorBayram, N
dc.contributor.authorAycan, O
dc.contributor.authorTaskapan, H
dc.date.accessioned2024-08-04T20:14:57Z
dc.date.available2024-08-04T20:14:57Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground. Demodex folliculorum (DF), found in the pilosebaceous unit, is the most common ectoparasite in humans. It has been implicated in various clinical lesions such as pustular folliculitis, papulopustular scalp eruption, perioral dermatitis, and skin lesions of immunosuppressed patients on chemotherapy or with acquired immunodeficiency syndrome (AIDS). Objective. We aimed to determine DF carriers and location of DF among patients on chronic dialysis because of end stage renal failure (ESRF), to compare them with healthy controls, and to examine the relationship between DF incidence and dialysis method and symptoms. Methods. Sixty-seven patients on dialysis and 67 healthy controls were taken into the study. The patient groups were classified according to the diseases causing ESRF [diabetes mellitus (DM), polycystic disease (PCD), glomerulonephritis (GN), hypertensive nephrosclerosis (HTNS), others (OT), unknown etiology (UE)], and mode of dialysis. Five standardized skin surface biopsies (SSSB) were taken. The determination of five and more living parasites/cm(2) area was diagnosed as infestation. Results. The mean mite count in the ESRF group, 6.12/cm(2), was significantly higher than that in controls, 0.31/cm(2), (Independent Samples Test, p=0.000). The DF positivity according to primary disease causing ESRF revealed that it was most frequent in DM with 12 patients (44.4%), followed by UE with nine patients (33.4%). Conclusions. Our findings indicate that the DF number is increased in ESRF patients on dialysis treatment. We recommend that demodicidosis should be included in the differential diagnosis of facial eruptions in patients with ESRF.en_US
dc.identifier.doi10.1080/08860220500198037
dc.identifier.endpage499en_US
dc.identifier.issn0886-022X
dc.identifier.issue5en_US
dc.identifier.pmid16152985en_US
dc.identifier.scopus2-s2.0-24044501900en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage495en_US
dc.identifier.urihttps://doi.org/10.1080/08860220500198037
dc.identifier.urihttps://hdl.handle.net/11616/94076
dc.identifier.volume27en_US
dc.identifier.wosWOS:000231674500001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectdemodex folliculorumen_US
dc.subjectend stage chronic renal failureen_US
dc.subjecturemiaen_US
dc.titleIncidence of Demodex folliculorum in patients with end stage chronic renal failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu